(NASDAQ: TRVN) Trevena's forecast annual revenue growth rate of 143.13% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Trevena's revenue in 2024 is $3,125,000.On average, 1 Wall Street analysts forecast TRVN's revenue for 2024 to be $17,771,380, with the lowest TRVN revenue forecast at $17,771,380, and the highest TRVN revenue forecast at $17,771,380. On average, 1 Wall Street analysts forecast TRVN's revenue for 2025 to be $54,963,030, with the lowest TRVN revenue forecast at $54,963,030, and the highest TRVN revenue forecast at $54,963,030.
In 2026, TRVN is forecast to generate $968,998,219 in revenue, with the lowest revenue forecast at $968,998,219 and the highest revenue forecast at $968,998,219.